A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant
Clinical trial NCT05569421 · COMPLETED
Trial details
- NCT number
- NCT05569421
- Sponsor
- AstraZeneca
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-10-11
- Primary completion
- 2023-04-14
- Enrollment
- 108
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.